🔬 Latest pharma industry updates 👇

🤝 Roche acquires Poseida Therapeutics, Inc. for up to $1.5B, expanding into CAR-T therapies.

📉 U.S. overdose deaths declined by 14.5% to 97,000 over 12 months; experts credit increased treatment efforts and wider naloxone use.

🤝 Arrowhead Pharmaceuticals licenses muscle, CNS, and lung disease programs to Sarepta Therapeutics for $500M upfront and $325M in equity.

👁️ Recordati and Angelini Pharma are considering a merger to form Europe's largest generics group; discussions are preliminary.

🟢 FDA approves BridgeBio's heart drug for transthyretin amyloidosis, challenging Pfizer's tafamidis; shares surge nearly 25%.

💰 Novo Holdings is expected to receive EU approval on December 6 for $16.5B acquisition of Catalent Pharma Solutions.

⚖️ Amgen's obesity drug MariTide shows 20% weight loss in Phase II; investors disappointed by discontinuation rates compared to Eli Lilly and Company's drug.

👏 Anavex Life Sciences submits MAA to EMA for blarcamesine for Alzheimer's treatment.

❌ Biohaven's muscle drug fails in SMA study, potentially removing competition for Scholar Rock.

📊 embecta reports strong revenues of $1.12B, discontinues insulin patch pump, cuts 60% of workforce to focus on core diabetes care; shares rise 30%

👏 Axsome Therapeutics, Inc. reports positive Phase 3 results for narcolepsy drug AXS-12; plans to file for FDA approval.

💔 Kronos Bio to lay off 83% of workforce; CEO steps down as the company halted ovarian cancer program and strategic review.

💰 PTC Therapeutics, Inc. sells Rare Pediatric Disease Priority Review Voucher for $150M after FDA approval of Kebilidi.

📊 EMA launches a medicine shortages monitoring platform to track drug availability in Europe.

💔 Alector lays off 41 employees after Alzheimer's drug AL002 fails to meet key endpoints; shares drop nearly 30%.

💰 Grifols seeks to refinance €1.4B in debt after Brookfield withdraws bid; prepares to present strategic plan to investors.

⚠️ Roche's cancer drug tiragolumab fails Phase 3 trial; adding it to Tecentriq did not improve survival in lung cancer patients.